"Duct tape is the single greatest invention of the 20th century. By contrast, all the 21st century has been able to bring us so far is cloned sheep. As if bovine molestation were not already a problem of epidemic proportions..."
moshpit (if you just gotta rant back, use the pit, that's what it's for.)
Achtung! Das machine ist nicht fur gerfingerpoken und mittengraben. Ist easy schnappen der pringenwerk, blowenfusen, und poppencorken mit spitzensparken. Ist nicht fur gewerken by das dumkopfen, das rubbernecken sightseeren keepen hands in der pockets, relaxen und watchen der blinkenlights.
DISCLAIMER: Title Goes Here(tm) hereby expressly disclaims any implied warranties imputed by the laws of any jurisdiction whatsoever. We consider ourselves and intend to be subject to the jurisdiction only of the courts of the state of Chilikonkarne, Lower Moldavia. If you are dissatisfied with this site or with any terms, conditions, rules, policies, guidelines or practices herein, kindly piss off. Title Goes Here(tm) exists to serve Title Goes Here(tm). Title Goes Here(tm) is expressly NOT concerned with your satisfaction in any way, shape, or form. Title Goes Here(tm) is not responsible for any errors, omissions or representations on any of our pages or on any links on any of our pages. Nor does Title Goes Here(tm) warrant that the use of this information is free of any claims of copyright infringement. In short, Title Goes Here(tm) is responsible for exactly jack shit. We totally stole this disclaimer from EasyMidget, and we're sure they'd be the first to applaud us for it.
FAIR USE NOTICE
This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: Cornell Univeristy Law Center. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.
Been busy remodeling my new place, now gonna be busy packing up and putting my old place on the market, so posts will be few and far between as the mood and the schedule allows. Here's today's lovely little gem, file under "its for your own good":
10 panelists in painkiller vote had ties to makers,study finds
By The Associated Press
WASHINGTON — Ten members of the Food and Drug Administration advisory panel that voted to allow a group of powerful painkillers to be sold despite safety concerns had ties to the drug makers, an advocacy group says.
A study by the Center for Science in the Public Interest indicates that the members in question had ties to either Pfizer or Merck, ranging from consulting fees and speaking honoraria to research support. Documents show that, without their votes, the panel would have recommended that Pfizer's Bextra and Merck's Vioxx not be sold in the United States.
After three days of hearings on the drugs, known as Cox-2 inhibitors, the panel voted 31-1 to keep Pfizer's Celebrex on the market, 17-13 with 2 abstentions in favor of Bextra and 17-15 for Vioxx.
A copy of the transcript indicated that the 10 members in question voted unanimously in favor of keeping Celebrex and Bextra available and 9-1 in favor of allowing Vioxx to be brought back onto the market.
Merck pulled Vioxx from the market Sept. 30 after heart problems were reported in some users. Similar questions were raised later about the other two drugs, prompting the FDA to have the advisory panel look into the matter.
The industry ties of the panel members were first reported yesterday by The New York Times.
The FDA issued a statement saying it screened members of the panel for conflicts of interest. "This transparent process requires the agency to carefully weigh any potential financial interest with the need for essential scientific expertise in order to protect and advance the public health," the agency said.
Because drug companies fund many studies, it is not unusual for researchers to have ties to manufacturers, although some have questioned the practice.
